DS2001a

DS2001a (also known as DS-2001) is an investigational small molecule inhibitor of the voltage-gated sodium channel 1.8 (Nav1.8), developed by Daiichi Sankyo. Nav1.8, encoded by the SCN10A gene, is a sodium channel isoform predominantly expressed in peripheral sensory neurons (nociceptors), where it plays a critical role in the initiation and propagation of action potentials in response to noxious stimuli. By selectively blocking Nav1.8, DS2001a aims to inhibit pain signaling at the source in the peripheral nervous system, potentially offering a non-opioid therapeutic option for various pain conditions with a reduced risk of central nervous system side effects. The compound has been evaluated in Phase 1 clinical trials, including a single ascending dose study in healthy volunteers in Japan (jRCT2031250859) to assess its safety, tolerability, and pharmacokinetic profile.